With the COVID-19 public health emergency expected to come to an end sometime in early 2023, FDA is preparing to help drug makers transition from emergency use authorization to full approval and will continue to focus on curbing ongoing drug shortages, including by updating its drug shortage guidance to include details about risk management plans that drug makers are now required to have in place, Valerie Jensen, director of FDA’s drug shortage staff, said Wednesday (Dec. 1). The COVID-19 PHE...